

- patients with clear cell carcinoma of the ovary treated with platinum versus nonplatinum-based chemotherapy. *Cancer*. 1996;78:2157–2163.
5. Sugiyama T, Kamura T, Kigawa J, et al. Clinical characteristics of clear cell carcinoma of the ovary. *Cancer*. 2000;88:2584–2589.
 6. Pectasides D, Fountzilas G, Aravantinos G, et al. Advanced stage clear-cell epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience. *Gynecol Oncol*. 2006;102:285–291.
 7. Enomoto T, Kuragaki C, Yamasaki M, et al. Is clear cell carcinoma and mucinous carcinoma of the ovary sensitive to combination chemotherapy with paclitaxel and carboplatin? *J Clin Oncol*. 2003;22(abstract 1797).
 8. Ho CM, Huang YJ, Chen TC, et al. Pure-type clear cell carcinoma of the ovary as a distinct histological type and improved survival in patients treated with paclitaxel-platinum-based chemotherapy in pure-type advanced disease. *Gynecol Oncol*. 2004;94:197–203.
 9. Takano M, Kikuchi Y, Yaegashi N, et al. Clear cell carcinoma of the ovary: a retrospective multicentre experience of 254 patients with complete surgical staging. *Br J Cancer*. 2006;94:1369–1374.
 10. FIGO Cancer Committee. Staging announcement. *Gynecol Oncol*. 1986;25:383.
 11. Kennedy AW, Markman M, Biscotti CV, et al. Survival probability in ovarian clear cell adenocarcinoma. *Gynecol Oncol*. 1999;74:108–114.
 12. O'Brien ME, Schofield JB, Tan S, et al. Clear cell epithelial ovarian cancer (mesonephroid): bad prognosis only in early stages. *Gynecol Oncol*. 1993;49:250–254.
 13. Jenison EL, Montag AG, Griffiths CT, et al. Clear cell adenocarcinoma of the ovary: a clinical analysis and comparison with serous carcinoma. *Gynecol Oncol*. 1989;32:65–71.
 14. Ho CM, Chien TY, Shih BY, et al. Evaluation of complete surgical staging with pelvic and para-aortic lymphadenectomy and paclitaxel plus carboplatin chemotherapy for improvement of survival in stage I ovarian clear cell carcinoma. *Gynecol Oncol*. 2003;88:394–399.
 15. Suzuki S, Kajiyama H, Shibata K, et al. Is there any association between retroperitoneal lymphadenectomy and survival benefit in ovarian clear cell carcinoma patients? *Ann Oncol*. 2008;19:1284–1287.
 16. Timmers PJ, Zwinderman AH, Teodorovic I, et al. Clear cell carcinoma compared to serous carcinoma in early ovarian cancer: same prognosis in a large randomized trial. *Int J Gynecol Cancer*. 2009;19:88–93.
 17. Trimbois JB, Vergote I, Bolis G, et al. European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer—Adjuvant Chemotherapy in Ovarian Neoplasm trial. *J Natl Cancer Inst*. 2003;95:113–125.
 18. Trimbois B, Timmers P, Pecorelli S, et al. Surgical staging and treatment of early ovarian cancer: long-term analysis from a randomized trial. *J Natl Cancer Inst*. 2010;102: 982–987.
 19. Cass I, Li AJ, Runowicz CD, et al. Pattern of lymph node metastases in clinically unilateral stage I invasive epithelial ovarian carcinomas. *Gynecol Oncol*. 2001;80:56–61.
 20. Morice P, Joulie F, Camatte S, et al. Lymph node involvement in epithelial ovarian cancer: analysis of 276 pelvic and paraaortic lymphadenectomies and surgical implications. *J Am Coll Surg*. 2003;197:198–205.
 21. Negishi H, Takeda M, Fujimoto T, et al. Lymphatic mapping and sentinel node identification as related to the primary sites of lymph node metastasis in early stage ovarian cancer. *Gynecol Oncol*. 2004;94:161–166.
 22. Takeshima N, Hirai Y, Umayahara K, et al. Lymph node metastasis in ovarian cancer: difference between serous and non-serous primary tumors. *Gynecol Oncol*. 2005;99: 427–431.
 23. Takano M, Sugiyama T, Yaegashi N, et al. The impact of complete surgical staging upon survival in early-stage ovarian clear cell carcinoma: a multi-institutional retrospective study. *Int J Gynecol Cancer*. 2009;19:1353–1357.
 24. Leitao MM Jr, Boyd J, Hummer A, et al. Clinicopathologic analysis of early-stage sporadic ovarian carcinoma. *Am J Surg Pathol*. 2004;28:147–159.
 25. Mizuno M, Kikkawa F, Shibata K, et al. Long-term prognosis of stage I ovarian carcinoma. Prognostic importance of intraoperative rupture. *Oncology*. 2003;65:29–36.

